Chih-Wei Chang

I lead transformative drug discovery initiatives, achieving significant milestones in preclinical candidate development. • Directed a 20-member team, fostering collaboration across functions and enhancing project outcomes. • Employed advanced CADD and AI technologies to design novel compounds, driving innovation in medicinal chemistry and ensuring project success within budget constraints. • Mentored the next generation of chemists, ensuring knowledge transfer and skill development within the team.

• Managed a team of approximately 200 chemists specializing in the synthesis of diverse drug-like molecules, including PROTACs, Molecular glue, ADC components, lipids, polypeptides, nucleotides, oligosaccharides, and covalent inhibitors. • Integrated resources for drug discovery, collaborated with global experts, and ensured seamless communication with clients. • Provided extensive support for Hit to Lead services, DELight and fragment-based drug discovery programs, and high-throughput screening. • Assisted in structure-based design for lead optimization. • Utilized CADD platforms to predict drug activity, DMPK profiles, toxicity, and hERG liability.

• Complete multiple contract researches (CRO) including relocation of resource, milestone and communication to meet up the timeline set in agreements and report to the executive board of industry partners; resulted in 2 awarded patents (WO2019113645, WO2019113646) and clinical trial (Investigational Product name: STC314) • Lead and manage multiple medicinal chemistry research projects in fields of therapeutic development against sepsis, antiviral and anticancer including SAR analysis, drug design, synthesis optimization- resulted in 5 publications including Nature Chem Bio, Chemical Science, ACS Infectious Disease • Translate half-kilo scale synthetic protocol to CMO company for production GMP batch of drug candidate (mCBS) up to 7 KG • Patent filing and management; Draft of specification and communication with patent attorney • Experience in Computer-Aided Drug Design (CADD) and prediction of drug-like property using in silico tools

• Successfully completed total synthesis of natural product served as potential anti-HIV agent • Development of new synthetic methodology including design of new chiral ligand and organocatalyst for asymmetric synthesis; resulted in 3 publications

• Pivotal team member involved in small molecule drug discovery project; engaged in processes including HTS, hit validation, lead optimization, structure-based drug design, biological evaluation, formulation for in vivo pre-clinical study, acute toxicity, cytochrome P450 testing, DMPK/ADME evaluation; resulted in 1 granted patent 2000-2002 Procurement Representative/ Lab Manager - TaiGen Biotechnology Company Ltd, Taipei, R.O.C. • Lead lab management team to set up SOP for improving efficiency in drug research pipeline Engaged in lab design and infrastructure construction for capacity of 30 synthetic chemists; in charge of international procurement of HTS compounds (300K) and research instruments